Details
Stereochemistry | RACEMIC |
Molecular Formula | C30H33Cl2F2N5O2 |
Molecular Weight | 604.518 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1CN(CCCCC(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3)CCN1CC(=O)NC4=C(Cl)C=C(N)C=C4Cl
InChI
InChIKey=IWMYIWLIESDFRZ-UHFFFAOYSA-N
InChI=1S/C30H33Cl2F2N5O2/c31-25-15-23(35)16-26(32)29(25)37-28(40)18-39-14-13-38(17-27(39)30(36)41)12-2-1-3-24(19-4-8-21(33)9-5-19)20-6-10-22(34)11-7-20/h4-11,15-16,24,27H,1-3,12-14,17-18,35H2,(H2,36,41)(H,37,40)
Draflazine is a member of the lidoflazine. Draflazine is a potent inhibitor of equilibrative nucleoside transporters (ENTs). It is more selective for ENT1 relative to ENT2. Draflazine is cardioprotective due to potentiation of receptor-mediated effects of adenosine in the ischemic myocardium. It has also been tested for enhancing cardiac functionality in isolated hearts during storage or transport for transplant operations. Draflazine exhibits overactive bladder activity. It is not yet approved for clinical use.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23091396
Single dose - 10 mg/kg
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
||
|
NCI_THESAURUS |
C78322
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1628717
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY | |||
|
FF-48
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY | |||
|
120770-34-5
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY | |||
|
60849
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY | |||
|
100000080816
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY | |||
|
6752
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY | |||
|
SUB06395MIG
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY | |||
|
C76030
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY | |||
|
0Y25DT968Y
Created by
admin on Fri Dec 15 15:36:46 GMT 2023 , Edited by admin on Fri Dec 15 15:36:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY